Ansbert Gadicke - Sep 14, 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Director, 10%+ Owner
Signature
/s/ Ansbert Gadicke
Stock symbol
CGEM
Transactions as of
Sep 14, 2021
Transactions value $
-$449,174
Form type
4
Date filed
9/16/2021, 04:44 PM
Previous filing
Sep 13, 2021
Next filing
Mar 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Sale -$28.6K -982 -0.4% $29.17 246K Sep 14, 2021 Direct F1, F2
transaction CGEM Common Stock Sale -$207K -7.11K -0.09% $29.17 7.66M Sep 14, 2021 See Footnote F1, F2, F3, F4
transaction CGEM Common Stock Sale -$25.9K -888 -0.36% $29.16 245K Sep 15, 2021 Direct F1, F5
transaction CGEM Common Stock Sale -$187K -6.43K -0.08% $29.16 7.65M Sep 15, 2021 See Footnote F1, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
F4 The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.43 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.